Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer.
Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer. J Chemother. 2020 Feb 18;:1-5 Authors: Maruta M, Miyoshi T, Matsuo N, Yamashina T, Irie K, Tsuruta M, Tsukada H, Tsuruyama M, Nagano M, Hiraki Y Abstract We administered FOLFOX (oxaliplatin (L-OHP) plus infusional 5-fluorouracil (5-FU) and leucovorin) to an hemodialysis (HD) patient with advanced gastric cancer (AGC), and investigated pharmacokinetics (PKs) and dialyzability of L-OHP. The patient was a 54-year-old Japanese man with a diagnosis of inoperable AGC. FOLFOX was instituted 3 h prior to the start of a 4 h HD period with the L-OHP and 5-FU doses reduced by 50% for the first cycle, and 30% reduced dose was administered for the second cycle. We performed an analysis of the PKs of L-OHP during these two cycles. Volume of distribution and area under the curve of the 30% reduced L-OHP dose were 56.7 L and 30.0 μg·h/mL, respectively. A dose reduction of L-OHP by 30%-50% may be advisable for the initial administration, given the need for careful administration of chemotherapy in HD patients, with particular attention to the development of hematological toxicities and neuropathy. PMID: 32066346 [PubMed - as supplied by publisher]
In conclusion, sitagliptin may have a potential inhibitory effect on GC by AMPK/YAP/melanoma‐associated antigen‐A3 pathway.
Condition: Gastric Cancer Intervention: Procedure: Magnetic anchored guided endoscopic submucosal dissection Sponsor: First Affiliated Hospital Xi'an Jiaotong University Not yet recruiting
Contributor : Haiwei NiSeries Type : Expression profiling by arrayOrganism : Homo sapiensmiR-375 plays an irreplaceable role in regulation of neoplastic progression in gastric cancer. In order to study the mechanism by which miR-375 inhibits the stemness of gastric cancer cell lines, we need to explore the genetic program controlled by miR-375.We used microarrays to detail the global program of gene expression underlying miR-375 up-regulation and identified distinct classes of regulated genes during this process.
CONCLUSIONS EphA1 can promote the occurrence and development of GC by its selective high expression in cancer tissues and its relationship with malignant clinical features and prognosis of GC patients. The underlying potential mechanism appears to involve enhancement of the tumor microenvironment, which via drives the expression of tumor microenvironment hallmark proteins IL-6 and VEGF. PMID: 32218416 [PubMed - as supplied by publisher]
Cell Death &Disease, Published online: 30 March 2020; doi:10.1038/s41419-020-2398-zPCDHGA9 represses epithelial-mesenchymal transition and metastatic potential in gastric cancer cells by reducing β-catenin transcriptional activity
Journal of Laparoendoscopic&Advanced Surgical Techniques, Ahead of Print.
Authors: Tian X, Wang N Abstract Pancreatic ductal adenocarcinoma (PDAC) remains a major cause of cancer-associated mortality, with poor patient outcome. The present study aimed to identify key candidate genes and investigate the potential molecular mechanisms associated with the progression of PDAC. The GSE46234 dataset was downloaded from the Gene Expression Omnibus database, in order to identify the upregulated differentially expressed genes (DEGs) in PDAC. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to determine the biological functions and pathways of the upreg...
Publication date: Available online 28 March 2020Source: Pathology - Research and PracticeAuthor(s): Sangjoon Choi, Jiryeon Jang, You Jeong Heo, So Young Kang, Seung Tae Kim, Jeeyun Lee, Won Ki Kang, Jong-Won Kim, Kyoung-Mee Kim
This study suggests that increased CREBZF by hsa-miR-421/hsa-miR-29b-1-5p inhibition may be important to prevent the progression of gastric cancer in its early stage. PMID: 32218690 [PubMed - as supplied by publisher]
Authors: Li W, Zhou Y, Shang C, Sang H, Zhu H Abstract Background: Proton pump inhibitor (PPI) and other acid-suppressing drugs are widely used in the treatment of gastrointestinal ulcer, upper gastrointestinal bleeding, gastritis, and gastric cancer (GC). About 80% of GC patients receive acid suppression treatment. PPI suppresses the production of gastric acid by inhibiting the function of H+/K+-ATPase in gastric parietal cells and raises the pH value to achieve therapeutic purposes. Some studies have found that PPI had a certain antitumor effect in the proliferation and apoptosis of tumor cells. But the effects o...